Page 100 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 3 ฉบับที่ 3

98 «“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë Û ©∫—∫∑’Ë Û ¡‘∂ÿπ“¬π -°—𬓬π ÚıÙ¯

‡π◊ËÕß®“°µâ𧔷 ¥æ∫‰¥âµ“¡ªÉ“¥‘∫·≈âß¡’¡“°∑“ß¿“§‡Àπ◊Õ (4) ·≈–ª≈Ÿ°‰¥â∑ÿ°¿“§
(5)
∑—Ë«‰ª ∑”„Àâ “¡“√∂À“«—µ∂ÿ¥‘∫„π°“√ °—¥ ’‰¥âßà“¬ ¥—ßπ—Èπ°≈ÿà¡«‘®—¬·≈–æ—≤π“º≈‘µ¿—≥±å ∂“∫—π«‘®—¬
¡ÿπ‰æ√ ®÷߉¥â‡µ√’¬¡ “√ °—¥‡¡≈Á¥§”· ¥‚¥¬«‘∏’∑’Ëæ—≤π“¢÷Èπ ‡æ◊ËÕ„™â‡ªìπ feed additive ·µàß ’„π
º≈‘µ¿—≥±åµà“ßÊ ´÷Ëß®–™à«¬≈¥°“√π”‡¢â“ ’ annatto ®“°µà“ߪ√–‡∑»‰¥â Õ¬à“߉√°Áµ“¡®”‡ªìπ∑’Ë®–µâÕß
»÷°…“§«“¡‡ªìπæ‘…¢Õß “√ °—¥ ’∑’ˇµ√’¬¡®“°‡¡≈Á¥§”· ¥ ºŸâ«‘®—¬®÷߉¥â»÷°…“æ‘…‡©’¬∫æ≈—π·≈–

°÷Ë߇©’¬∫æ≈—π¢Õß “√ °—¥‡¡≈Á¥§”· ¥‡æ◊ËÕ„À≥â¢âÕ¡Ÿ≈∑“ßæ‘…«‘∑¬“‡∫◊ÈÕßµâπ°àÕπ𔉪·µàß ’Õ“À“√
·≈–º≈‘µ¿—≥±å ÿ¢¿“æµà“ßÊ µàÕ‰ª

∫∑§—¥¬àÕ

‰¥â»÷°…“§«“¡‡ªìπæ‘…¢Õß “√ °—¥‡¡≈Á¥§”· ¥∑’ˇµ√’¬¡¢÷Èπ‚¥¬°≈ÿà¡«‘®—¬·≈–æ—≤π“º≈‘µ¿—≥±å
¡ÿπ‰æ√ ∂“∫—π«‘®—¬ ¡ÿπ‰æ√ æ∫«à“ ‡¡◊ËÕ„Àâ “√ °—¥‡¡≈Á¥§”· ¥·°àÀπŸ∂’∫®—°√∑“ߪ“°¢π“¥ Ÿß ÿ¥§◊Õ

16.0 °./°°. ‰¡à∑”„À⇰‘¥Õ“°“√æ‘…‡©’¬∫æ≈—π·≈–ÀπŸ‰¡àµ“¬ ®“°°“√»÷°…“æ‘…°÷Ë߇©’¬∫æ≈—π√–¬–‡«≈“
28 «—π „πÀπŸ·√∑«‘ µ“√å ®”π«π 150 µ—«·∫àßÕÕ°‡ªìπ 5 °≈ÿà¡Ê≈– 15 µ—«µàÕ‡æ» ª√–°Õ∫¥â«¬°≈ÿà¡
§«∫§ÿ¡ªÑÕππÈ”°≈—Ëπ ·≈–°≈ÿà¡∑¥≈Õ߉¥â√—∫ “√ °—¥‡¡≈Á¥§”· ¥∑“ߪ“°„π¢π“¥ 0.24, 2.4, 12.0, ·≈–

60.0 ¡°./°°./«—π ‰∑¬ß„Àâ‡ÀÁπ«à“ “√ °—¥‰¡à¡’º≈µàÕπÈ”Àπ—°µ—« °“√°‘πÕ“À“√ πÈ”Àπ—°Õ«—¬«– —¡æ—∑∏å
§à“∑“߇§¡’§≈‘π‘°·≈–‰¡à∑”„À⇰‘¥Õ“°“√æ‘… – ¡ à«π°“√‡æ‘Ë¡¢÷Èπ¢Õßπ‘«‚∑√øî≈„πÀπŸ‡æ»ºŸâ°≈ÿà¡∑’ˉ¥â
√—∫ “√ °—¥¢π“¥ 12.0 ·≈– 60.0 ¡°./°°./«—π ¬—ßÕ¬Ÿà„π™à«ß§à“ª°µ‘·≈–®—¥‡ªìπ minor change

º≈°“√ºà“´“°™—π Ÿµ√‰¡àæ∫°“√‡ª≈’ˬπ·ª≈ß∑“ß¡À欓∏‘«‘∑¬“ (gross pathological lesions)¢Õß
Õ«—¬«–¿“¬„π ®“°°“√µ√«®™‘Èπ‡π◊ÈÕÕ«—¬«–∑“ß®ÿ≈欓∏‘«‘∑¬“· ¥ß„Àâ‡ÀÁπ«à“ ÀπŸ∑’ˉ¥â√—∫ “√ °—¥‡¡≈Á¥
§”· ¥‰¡à¡’§«“¡º‘¥ª°µ‘¢ÕßÕ«—¬«–¿“¬„πµà“ßÊ ¬°‡«âπÀπŸ‡æ»ºŸâ°≈ÿà¡∑’ˉ¥â√—∫ “√ °—¥¢π“¥ Ÿß ÿ¥¡’

Õÿ∫—µ‘°“√≥å¢Õ߇´≈≈åµ—∫‡ ◊ËÕ¡·∫∫‰¢¡—π Ÿß¢÷Èπ·µà°“√‡ª≈’ˬπ·ª≈ßπ’ȇªìπ√–¥—∫ mild fatty change ‡∑à“π—Èπ
¥—ßπ—Èπ°“√„™â “√ °—¥‡¡≈Á¥§”· ¥∑’ˇµ√’¬¡¢÷Èπ‡ªìπ “√·µàß ’‰¡à§«√„™âª√‘¡“≥ ŸßÀ√◊Õ‡¢â¡¢âπ¡“°‡°‘π‰ª
·≈–§«√æ‘®“√≥“∂÷ߪ√‘¡“≥ “√ ”§—≠∑’Ë¡’Õ¬Ÿà„π “√ °—¥‰¥â·°à bixin ·≈– norbixin ¥â«¬‡æ◊ËÕª√—∫
¢π“¥„Àâ‡À¡“– ¡°—∫Õ“À“√·µà≈–ª√–‡¿∑¥—ß√“¬ß“π°“√„™â “√ °—¥·Õπ·πµ¢Õߪ√–‡∑»Õ◊ËπÊ ¥â«¬

ABSTRACT
Toxicity study of Bixa orellana Linn. extract, produced by Medicinal Plant

Research Institute was investigated. The maximum dose of 16.0 g/kg extract was orally
administered to mice and it was shown that the extract cause no acute toxic signs and
no death. Oral subacute toxicity study in five group of Wistar rats consisting of water

control and four extract-treated groups at the doses of 0.24, 2.4, 12.0 and 60.0 mg/kg/day
revealed that the extract did not cause any toxic sign and there was no alteration on body